Poseida Therapeutics, Inc. (Nasdaq: PSTX) (“Poseida”), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, announces that it has entered into a merger agreement to be acquired by Roche Holdings, Inc. (“Roche”) at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones. This corresponds to a total equity value of approximately $1.5 billion on a fully diluted basis.
Read the full article: Poseida Therapeutics, Inc. Announces Agreement to Be Acquired by Roche Holdings, Inc. //
Source: https://www.prnewswire.com/news-releases/poseida-therapeutics-inc-announces-agreement-to-be-acquired-by-roche-holdings-inc-302316189.html